Keywords: aventis, says, human, vaccines, business, maintain, double-digit
Aventis says human vaccines business will maintain double-digit growth
Article | 6 October 2003
Franco-German pharmaceutical major Aventis highlighted its human vaccines business at a meeting of investment analysts late-September, at which it said ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- UK's NICE does U-turn, recommending Zytiga as Janssen cuts price
- ABPI chief asks: Is saving money more important than saving lives?
- Ambitious growth targets set for Bayer Healthcare in 2014
- GlaxoSmithKline buys full control of Cellzome
- Ophthalmic drugs market set for $18.7 billion value in 2012, says Visiongain
